SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $8.41 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2020-11-06
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-09-30 was -$2.50M, a 203.13% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-06-30 was $14.55M, a 677.91% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2020-03-31 was -$3.63M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-12-31 was -$4.93M, a 210.41% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2019 was -$3.81M, a 136.53% decline from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2018 was $10.43M, a 261.22% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2017 was $2.89M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $12.04M derived: sum of 2 quarters · filed 2020-11-06 | $8.41M 10-Q · filed 2020-11-06 | $3.48M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-06-30 | $14.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $10.91M 10-Q · filed 2020-08-17 | $5.98M derived: sum of 3 quarters · filed 2020-08-17 | $8.41M derived: sum of 4 quarters · filed 2020-11-06 |
| 2020-03-31 | -$3.63M 10-Q · filed 2020-05-15 | -$8.56M derived: sum of 2 quarters · filed 2020-05-15 | -$6.14M derived: sum of 3 quarters · filed 2020-11-06 | -$4.27M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-12-31 | -$4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$2.50M derived: sum of 2 quarters · filed 2020-11-06 | -$634.00K derived: sum of 3 quarters · filed 2020-11-06 | -$3.81M 10-K · filed 2020-02-28 |
| 2019-09-30 | $2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $4.30M derived: sum of 2 quarters · filed 2020-11-06 | $1.12M 10-Q · filed 2020-11-06 | $5.59M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | -$1.31M 10-Q · filed 2020-08-17 | $3.16M derived: sum of 3 quarters · filed 2020-08-17 | $6.16M derived: sum of 4 quarters · filed 2020-08-17 |
| 2019-03-31 | -$3.18M 10-Q · filed 2020-05-15 | $1.29M derived: sum of 2 quarters · filed 2020-05-15 | $4.29M derived: sum of 3 quarters · filed 2020-05-15 | $8.39M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $7.47M derived: sum of 2 quarters · filed 2020-02-28 | $11.56M derived: sum of 3 quarters · filed 2020-02-28 | $10.43M 10-K · filed 2020-02-28 |
| 2018-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $7.10M derived: sum of 2 quarters · filed 2019-11-08 | $5.97M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $2.96M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | -$1.13M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $2.89M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |